Frontlight ResearchEarly access
Taking peopleNo phase
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
Key facts
- Who runs it
- Peking University First Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 70 people, planned
- Started
- 25 Apr 2026
- Expected to end
- 13 Feb 2027
- Type of study
- Interventional
- Treatments tested
- Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days
- Record updated
- 30 April 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Aged 18-70 years
- Positive results for both ¹³C-urea breath test (¹³C-UBT) and fecal polymerase chain reaction (PCR), confirming Helicobacter pylori infection, with a clinical indication for H. pylori eradication as judged by the physician
- Treatment-naïve individuals with no prior history of H. pylori eradication therapy
Who cannot take part
- Patients with a history of allergy to any drugs used in the eradication regimen
- Patients with severe systemic diseases or malignant tumors
- History of gastric resection surgery
- Recent use of antibiotics or bismuth salts (within 4 weeks), H₂-receptor antagonists, proton pump inhibitors (PPIs), or Potassium-competitive acid blockers(P-CABs) (within 2 weeks)
- Pregnant or lactating women
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.
The group in the trial
- ExperimentalTreatment being tested
Vonoprazan 20mg twice a day + clarithromycin 500mg twice a day
Treatment: Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Simplified Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line Helicobacter Pylori Eradication
- Criteria questions
- Built from NCT07439445, who can take part
- Record updated
- 30 April 2026